| Document Date: 2014-04-23 16:33:01
Open Document File Size: 396,72 KBShare Result on Facebook
City Reference / / Company Treatment Criteria Laboratory / Janssen Biotech Inc. / / Currency pence / / Event FDA Phase / / IndustryTerm resuscitation equipment / / MedicalCondition anaphylactic reaction / rash maculo papular / rash popular and rash pruritic / HIV / hematological and non-hematological malignancies / chest pain / Multiple Myeloma / disease / flushing / arthralgia / Anaphylactic reaction SYLVANT / Carcinogenesis / nausea / anaphylaxis / erythema / fever / Severe hypersensitivity / pain / vomiting / allergic reactions / another hematologic disease / Concurrent Active Severe Infections / Hypersensitivity / diarrhea / infection / severe infections / end stage renal disease / Indolent Multiple Myeloma / inflammation / pruritus / infections / rash / back pain / multicentric Castleman’s disease / upper respiratory tract infection / Hypotension / / MedicalTreatment oral contraceptives / contraception / Retreatment / resuscitation / Vaccinations / Intravenous infusion / / Organization DOSAGE AND ADMINISTRATION / FDA / Distribution Following SYLVANT administration / / Person Edema / / / Position Thrombocytopenia General / General / / Product acetaminophen / theophylline / cyclosporine / Dextrose / lovastatin / Sterile Water for Injection / SYLVANT solution / / Technology Pharmacokinetics / antibodies / Pharmacodynamics / / URL www.fda.gov/medwatch / /
SocialTag |
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SYLVANT™ safely and effectively. See full prescribing information for SYLVANT. SYLVANT (siltuximab) for Injection,